Aurora Therapeutics halts its custom CRISPR program and cuts staff after competitor Beam moves ahead
read at STAT ↗LayoffsNegative
Aurora Therapeutics, a startup developing personalized gene-editing drugs, announced it is abandoning its lead CRISPR program.
The decision came just seven months after the company launched, and it also triggered a reduction in staff, though the exact number of layoffs was not disclosed.
The move appears to be driven by competition from Beam Therapeutics, which recently reported progress on its own custom gene-editing platform for the same disease area.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans”
read at STAT ↗500 words · retrieved Aug 4
comments(0)
5-min edit window · permanent after that